search icon
adxn-img

Addex Therapeutics Ltd, Common Stock

ADXN

NAQ

$7.39

-$0.26

(-3.4%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$7.90M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
74.80K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.87
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.45 L
$27.9 H
$7.39

About Addex Therapeutics Ltd, Common Stock

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot"Marie"Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameADXNSectorS&P500
1-Week Return-9.88%0.31%-1.26%
1-Month Return-5.86%0.6%-4.16%
3-Month Return-29.62%-9.44%-0.46%
6-Month Return-11.18%-5.15%3.58%
1-Year Return5.92%0.33%22.47%
3-Year Return-93.81%4.53%25.13%
5-Year Return-97.45%35.98%77.7%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue2.76M3.61M2.92M1.42M1.61M[{"date":"2019-12-31","value":76.47,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":80.72,"profit":true},{"date":"2022-12-31","value":39.37,"profit":true},{"date":"2023-12-31","value":44.65,"profit":true}]
Cost of Revenue230.10K10.37M12.82M14.62M6.94M[{"date":"2019-12-31","value":1.57,"profit":true},{"date":"2020-12-31","value":70.94,"profit":true},{"date":"2021-12-31","value":87.66,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":47.43,"profit":true}]
Gross Profit2.53M(6.76M)(9.90M)(13.20M)(5.32M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-266.92,"profit":false},{"date":"2021-12-31","value":-390.97,"profit":false},{"date":"2022-12-31","value":-521.22,"profit":false},{"date":"2023-12-31","value":-210.15,"profit":false}]
Gross Margin91.67%(187.12%)(339.55%)(928.06%)(329.99%)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-204.12,"profit":false},{"date":"2021-12-31","value":-370.39,"profit":false},{"date":"2022-12-31","value":-1012.37,"profit":false},{"date":"2023-12-31","value":-359.97,"profit":false}]
Operating Expenses17.37M15.86M18.42M21.94M11.89M[{"date":"2019-12-31","value":79.15,"profit":true},{"date":"2020-12-31","value":72.26,"profit":true},{"date":"2021-12-31","value":83.96,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":54.21,"profit":true}]
Operating Income(14.83M)(12.24M)(15.51M)(20.52M)(10.28M)[{"date":"2019-12-31","value":-1483430800,"profit":false},{"date":"2020-12-31","value":-1224327400,"profit":false},{"date":"2021-12-31","value":-1550591700,"profit":false},{"date":"2022-12-31","value":-2052020700,"profit":false},{"date":"2023-12-31","value":-1028129900,"profit":false}]
Total Non-Operating Income/Expense(37.94K)(649.52K)96.31K(303.65K)(232.57K)[{"date":"2019-12-31","value":-39.39,"profit":false},{"date":"2020-12-31","value":-674.39,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-315.28,"profit":false},{"date":"2023-12-31","value":-241.47,"profit":false}]
Pre-Tax Income(14.78M)(12.86M)(15.35M)(20.80M)(10.56M)[{"date":"2019-12-31","value":-1478060400,"profit":false},{"date":"2020-12-31","value":-1285859900,"profit":false},{"date":"2021-12-31","value":-1535191400,"profit":false},{"date":"2022-12-31","value":-2080421300,"profit":false},{"date":"2023-12-31","value":-1055622700,"profit":false}]
Income Taxes128.52K207.76K116.38K123.91K21.61K[{"date":"2019-12-31","value":61.86,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":56.01,"profit":true},{"date":"2022-12-31","value":59.64,"profit":true},{"date":"2023-12-31","value":10.4,"profit":true}]
Income After Taxes(14.91M)(13.07M)(15.47M)(20.93M)(10.58M)[{"date":"2019-12-31","value":-1490912200,"profit":false},{"date":"2020-12-31","value":-1306636100,"profit":false},{"date":"2021-12-31","value":-1546829100,"profit":false},{"date":"2022-12-31","value":-2092812300,"profit":false},{"date":"2023-12-31","value":-1057783400,"profit":false}]
Income From Continuous Operations(14.78M)(12.86M)(15.35M)(20.80M)(10.56M)[{"date":"2019-12-31","value":-1478060400,"profit":false},{"date":"2020-12-31","value":-1285859900,"profit":false},{"date":"2021-12-31","value":-1535191400,"profit":false},{"date":"2022-12-31","value":-2080421300,"profit":false},{"date":"2023-12-31","value":-1055622700,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(14.78M)(12.86M)(15.35M)(20.80M)(10.56M)[{"date":"2019-12-31","value":-1478060400,"profit":false},{"date":"2020-12-31","value":-1285859900,"profit":false},{"date":"2021-12-31","value":-1535191400,"profit":false},{"date":"2022-12-31","value":-2080421300,"profit":false},{"date":"2023-12-31","value":-1055622700,"profit":false}]
EPS (Diluted)(0.62)(0.87)(2.99)(3.57)-[{"date":"2019-12-31","value":-62.18,"profit":false},{"date":"2020-12-31","value":-87.3,"profit":false},{"date":"2021-12-31","value":-299,"profit":false},{"date":"2022-12-31","value":-357.36,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ADXN
Cash Ratio 3.78
Current Ratio 4.59

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ADXN
ROA (LTM) -61.71%
ROE (LTM) -126.29%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ADXN
Debt Ratio Lower is generally better. Negative is bad. 0.09
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.91

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ADXN
Trailing PE NM
Forward PE NM
P/S (TTM) 10.43
P/B 0.66
Price/FCF NM
EV/R 8.81
EV/Ebitda NM

FAQs

What is Addex Therapeutics Ltd share price today?

Addex Therapeutics Ltd (ADXN) share price today is $7.39

Can Indians buy Addex Therapeutics Ltd shares?

Yes, Indians can buy shares of Addex Therapeutics Ltd (ADXN) on Vested. To buy Addex Therapeutics Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ADXN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Addex Therapeutics Ltd be purchased?

Yes, you can purchase fractional shares of Addex Therapeutics Ltd (ADXN) via the Vested app. You can start investing in Addex Therapeutics Ltd (ADXN) with a minimum investment of $1.

How to invest in Addex Therapeutics Ltd shares from India?

You can invest in shares of Addex Therapeutics Ltd (ADXN) via Vested in three simple steps:

  • Click on Sign Up or Invest in ADXN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Addex Therapeutics Ltd shares
What is Addex Therapeutics Ltd 52-week high and low stock price?

The 52-week high price of Addex Therapeutics Ltd (ADXN) is $27.9. The 52-week low price of Addex Therapeutics Ltd (ADXN) is $6.45.

What is Addex Therapeutics Ltd price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Addex Therapeutics Ltd (ADXN) is

What is Addex Therapeutics Ltd price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Addex Therapeutics Ltd (ADXN) is 0.66

What is Addex Therapeutics Ltd dividend yield?

The dividend yield of Addex Therapeutics Ltd (ADXN) is 0.00%

What is the Market Cap of Addex Therapeutics Ltd?

The market capitalization of Addex Therapeutics Ltd (ADXN) is $7.90M

What is Addex Therapeutics Ltd’s stock symbol?

The stock symbol (or ticker) of Addex Therapeutics Ltd is ADXN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top